



FcResolv[®] NOG Portfolio

The First and Only Super Immunodeficient Mouse Models that Remove Murine Fc Gamma Receptors Known to Confound Results

Murine Fc gamma receptors (Fc γ R) can confound preclinical studies involving antibody-based therapies. By knocking out these receptors, FcResolv[®] NOG models provide clarity in antibody-based drug studies, offering greater confidence and more translatable data while utilizing fewer resources.

FcResolv[®] models are suitable for engrafting a wide range of human cells and tissues, including simultaneous human tumor engraftment and immune system humanization.

KEY THERAPEUTIC AREAS

- Oncology and immuno-oncology
- Autoimmune disease
- Any therapeutic approach involving antibody-based drugs containing an Fc domain

KEY BENEFITS

GREATER CONFIDENCE IN YOUR STUDY RESULTS

Eliminate false positives and negatives that result when an antibody-based therapeutic's Fc domain interacts with murine Fc γ R

MORE ACCURATE ASSESSMENT OF ANTIBODY-BASED THERAPIES

Distinguish true drug efficacy from off-target effects mediated through the mouse immune system, and eliminate costly deconvolution steps

BETTER ANSWERS WITH FEWER RESOURCES


Avoid wasteful investments based on false positives or missing out on promising candidates due to false negatives

How FcResolv® NOG Models Work

The FcResolv® NOG model portfolio is based on the super immunodeficient CIEA NOG mouse®. This highly versatile strain lacks adaptive immune cells and has an attenuated innate immune response, yet still retains some residual mouse immune cells that can interact with therapeutic antibodies. FcResolv® NOG models eliminate this interaction by knocking out the activity of all murine FcγRs, including the FcγRI, IIB, III and IV types, along with the high affinity FcεRI receptor. The low affinity FcεRII receptor remains present.



Alleviate False Negatives Generated through Interaction Between Mouse FcγR and a Therapeutic's Fc Domain



FcγRs can confound experiments involving antibody-based therapies in several ways. This graphic depicts one mechanism.

Get to the right answer faster for your antibody-based therapy

Choose the FcResolv® mouse model that best suits your needs

Model Number	Name	Description
19164	FcResolv® NOG	Ideal for tumor xenografts using cell lines or patient-derived tumors, engraftment of other normal or pathological human cells and tissues, and immune system humanization studies
HSCCB-19164	FcResolv® huNOG	A humanized immune system mouse made by engrafting CD34+ hematopoietic stem cells (HSCs) in the FcResolv NOG strain
21552	FcResolv® NOG-EXL	Ideal for studies involving human myeloid cells; immuno-oncology and allergy applications; host for acute myeloid leukemia (AML) PDX
HSCCB-21552	FcResolv® huNOG-EXL	A humanized immune system mouse supporting both human lymphoid and myeloid cells, made by engrafting CD34+ HSCs in the FcResolv® NOG-EXL strain
19220	FcResolv® hIL-15 NOG	Supports engraftment of human NK cells, for use in efficacy studies on antibody-based therapeutics with an antibody-dependent cellular cytotoxicity (ADCC) mechanism of action

For more information, schedule a consultation on FcResolv® NOG models.
 US: 1-888-822-6642 | EU: +45 70 23 04 05 | info@taconic.com
 Learn more at: taconic.com/fcresolv

Scan the QR code
 to learn more about
 the FcResolv®
 NOG Portfolio

